TCF7L2-rs7903146 polymorphism modulates the effect of artichoke leaf extract supplementation on insulin resistance in metabolic syndrome: a randomized, double-blind, placebo-controlled trial

Ebrahimi-Mameghani, Mehrangiz; Asghari‐Jafarabadi, Mohammad; Rezazadeh, Khatereh

doi:10.1016/j.joim.2018.05.006

Cited by 26 publications

(37 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been demonstrated that transcription factor 7-like 2 (TCF7L2)-rs7903146 polymorphism is associated with increased risk of type 2 diabetes and the response of insulin. Insulin resistance to artichoke leaf extract (ALE) may be affected by TCF7L2-rs7903146 polymorphism [38,39].…”

Section: Discussionmentioning

confidence: 99%

The Metabolic Effects of Cynara Supplementation in Overweight and Obese Class I Subjects with Newly Detected Impaired Fasting Glycemia: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial

et al. 2020

View full text Add to dashboard Cite

Impaired fasting glucose (IFG) is a condition that precedes diabetes and increases the risk of developing it. Studies support the hypoglycemic effect of Cynarascolymus (Cs) extracts due to the content of chlorogenic acid, which is a potent inhibitor of glucose 6-phosphate translocase and of dicaffeoylquinic acid derivatives that modulate the activity of alpha-glucosidase. Given this background, we investigated whether a new highly standardized Cs extract could improve glycemic control, insulin sensitivity and other metabolic parameters (total cholesterol (TC), low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C) Triglycerides, Apolipo protein B (ApoB), Apolipo protein A (ApoA), waist circumference, visceral adipose tissue (VAT) by dual-energy X-ray absorptiometry (DXA) in overweight subjects with newly diagnosed IFG. Fifty-four subjects (females/males 26/28, mean ± SD age 51.5 ± 6.2) were randomly assigned to the supplemented group (n = 27) and placebo (n = 27). After multiple testing correction, statistically significant interactions between time and group were observed for the primary endpoint glycemia (β = 0.36, p < 0.0001) and for the secondary endpoints HDL (β = −0.10, p < 0.0001), total cholesterol/HDL (β = 0.27, p < 0.0001), LDL (β = 0.15, p = 0.005), LDL/HDL (β = 0.23, p = 0.001), insulin (β = 1.28, p = 0.04), glycated hemoglobin (β = 0.21, p = 0.0002), A1c-derived average glucose (β = 0.34, p = 0.0002), ApoB (β = 6.00, p = 0.01), ApoA (β = −4.50, p = 0.04), ApoB/ApoA (β = 0.08, p = 0.003), waist circumference (β = 1.89, p = 0.05), VATβ = 222.37, p = 0.005). In conclusion, these results confirm that Cs supplementation has a significant effect on metabolic parameters in IFG patients.

show abstract

Section: Discussionmentioning

confidence: 99%

The Metabolic Effects of Cynara Supplementation in Overweight and Obese Class I Subjects with Newly Detected Impaired Fasting Glycemia: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Traditionally, artichoke has been used as a remedy to treat hepato‐biliary disease and dyspepsia (LaGow, ). In previous in vitro and in vivo studies, extracts of artichoke heads and leaves have shown antimicrobial, hepatoprotective, cholerectic, hypocholesterlomic, hypoglycemic, and anticancer effects (Al‐Ahdab, ; Ebrahimi‐Mameghani, Asghari‐Jafarabadi, & Rezazadeh, ; El Sohaimy, ; Emanue, Adrian, Sultana, & Svetlana, ; Gebhardt & Fausel, ; Rezazadeh, Rahmati‐Yamchi, Mohammadnejad, Ebrahimi‐Mameghani, & Delazar, ; Rezazadeh, Rezazadeh, & Ebrahimi‐Mamaghani, ; Rondanelli et al, ; Rondanelli, Giacosa, Orsini, Opizzi, & Villani, ).…”

Section: Introductionmentioning

confidence: 99%

The antioxidant activity of artichoke (Cynara scolymus): A systematic review and meta‐analysis of animal studies

Salekzamani

Ebrahimi-Mameghani

Rezazadeh

2018

Phytotherapy Research

Self Cite

View full text Add to dashboard Cite

Current evidence has shown antioxidant activity of artichoke as a potent source of antioxidant compounds. However, it seems that the antioxidant activity of artichokehas not yet been reviewed. Therefore, the present study was designed to perform a systematic review of human studies, animal models, and in vitro systems and to conduct a meta-analysis of animal studies on the antioxidant effects of artichoke. We searched four electronic databases till April 2018 using relevant keywords. All English language articles were assessed. For animal studies, standardized mean difference was pooled using a random effects model. The included studies were evaluated for eligibility and risk of bias. Thirty-nine articles (two human, 23 animal, and 14 in vitro studies) were reviewed. The results of in vitro systems supported the antioxidant effect of artichoke, whereas limited clinical trials indicated no change or a slight improvement of antioxidant status. Finding of animal studies indicated that artichoke extract supplementation increased superoxide dismutase, catalase, glutathione, and glutathione peroxidase level in liver, as well as, decreased malondialdehyde level in liver and plasma of animals with induced disease significantly compared with comparison group. This meta-analysis provided convincing evidence for antioxidant activity of artichoke in animals.

show abstract

“…[ 72 ] reported in 49 non‐medicated women with MetS features the decrease of triglycerides versus placebo in those MetS that carried the A allele of rs9939609‐ FTO upon consumption of an artichoke leaf extract containing chlorogenic acid derivatives, while no interaction was observed with the SNP rs7903146‐ TCF7L2 . The same authors, [ 58 ] and using the same artichoke leaf extract, reported the decrease of insulin and HOMA‐IR in 68 non‐medicated MetS patients (the same 49 women plus 19 men), but only in those that carried the TT genotype of rs7903146‐ TCF7L2 . The apparent discrepancy with their previous study, regarding the interaction or not with rs7903146‐ TCF7L2 , was not discussed.…”

Section: Discussionmentioning

confidence: 94%

“…[24] In this regard, the drug therapy as a critical variable, and especially in MetS, has not generally been addressed since preclinical research with MetS models does not include drug therapy, and human interventions usually omit pharmacological treatments or mix medicated patients with non-medicated ones, or directly exclude MetS patients under medication. [14,15,52,58] Therefore, the challenging objective in the present trial was to evaluate possible adjuvant effects of a pomegranate extract (PE) nutraceutical in poly-medicated MetS patients, something unexplored so far. Besides, the possible prebiotic effects of polyphenols or derived food sources or nutraceuticals in poly-medicated MetS patients had not been approached so far.…”

Section: Discussionmentioning

confidence: 99%

Pharmacological Therapy Determines the Gut Microbiota Modulation by a Pomegranate Extract Nutraceutical in Metabolic Syndrome: A Randomized Clinical Trial

Cortés‐Martín

Iglesias‐Aguirre

Meoro

et al. 2021

Molecular Nutrition Food Res

View full text Add to dashboard Cite

Scope Poly‐pharmacological therapy shapes the gut microbiota (GM) in metabolic syndrome (MetS) patients. The effects of polyphenols in poly‐medicated MetS patients are unknown. Methods and results A randomized, placebo‐controlled, double‐blinded, and crossover trial in poly‐medicated MetS patients (n=50) explored whether the effects of a pomegranate extract nutraceutical (PE, 320 mg phenolics/day for 1 month) are affected by the drug therapy. Considering the lipid‐lowering (LL‐), anti‐hypertensive (HP‐) and(or) anti‐diabetic (AD‐) treatments: GM (16S rRNA sequencing), short‐chain fatty acids, 40 inflammatory‐metabolic and endotoxemia‐related biomarkers, associations between biomarkers and GM with 53 cardiometabolic dysfunctions‐related single‐nucleotide polymorphisms (SNPs), and urolithin metabotypes (UMs) influence are evaluated. Representative SNPs‐GM associations after PE include Lactococcus and ClostridiumXIVa with rs5443‐GNB3 (G‐protein‐β‐polypeptide‐3) and ClostridiumXIVa with rs7903146‐TCF7L2 (transcription‐factor‐7‐like‐2) and rs1137101‐LEPR (leptin‐receptor). PE decreases sICAM‐1 in LL‐patients and the lipopolysaccharide‐binding protein in all the patients. PE does not affect the other patients’ markers as a group or stratifying by UMs. After PE, Lactococcus increases in AD‐, LL‐, and HP‐patients, Bifidobacterium increases in LL‐ and AD‐, while Clostridium XIVa decreases in non‐LL‐ and non‐HP‐patients. Conclusion The prebiotic effect of PE depends on the medication, mainly on HP‐treatments. Targeting GM can complement MetS therapy, but the patients’ drug therapy should be considered individually.

show abstract

TCF7L2-rs7903146 polymorphism modulates the effect of artichoke leaf extract supplementation on insulin resistance in metabolic syndrome: a randomized, double-blind, placebo-controlled trial

Cited by 26 publications

References 40 publications

The Metabolic Effects of Cynara Supplementation in Overweight and Obese Class I Subjects with Newly Detected Impaired Fasting Glycemia: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial

The Metabolic Effects of Cynara Supplementation in Overweight and Obese Class I Subjects with Newly Detected Impaired Fasting Glycemia: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial

The antioxidant activity of artichoke (Cynara scolymus): A systematic review and meta‐analysis of animal studies

Pharmacological Therapy Determines the Gut Microbiota Modulation by a Pomegranate Extract Nutraceutical in Metabolic Syndrome: A Randomized Clinical Trial

Contact Info

Product

Resources

About